Enovis (NYSE:ENOV) Downgraded by Wall Street Zen to Hold

Wall Street Zen lowered shares of Enovis (NYSE:ENOV) from a buy rating to a hold rating in a report issued on Saturday morning,Wall Street Zen reports.

Other equities research analysts have also recently issued reports about the company. BTIG Research dropped their target price on Enovis from $40.00 to $36.00 and set a “buy” rating for the company in a report on Tuesday, September 1st. Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Canaccord Genuity Group cut their target price on shares of Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, August 17th. BMO Capital Markets set a $27.00 price target on Enovis in a report on Tuesday, September 1st. Finally, Citigroup restated a “market outperform” rating on shares of Enovis in a report on Wednesday, September 2nd. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Enovis presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.50.

Enovis Stock Performance

Shares of NYSE ENOV opened at $17.72 on Friday. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -0.92 and a beta of 1.37. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. Enovis has a 1-year low of $16.70 and a 1-year high of $34.28. The stock’s 50-day moving average is $21.74 and its 200 day moving average is $23.29.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The business had revenue of $582.78 million for the quarter, compared to analysts’ expectations of $581.84 million. During the same period last year, the business earned $0.79 earnings per share. The business’s quarterly revenue was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, sell-side analysts anticipate that Enovis will post 3.15 EPS for the current fiscal year.

Insider Activity

In other news, insider Oliver Engert purchased 5,140 shares of the business’s stock in a transaction on Thursday, September 3rd. The stock was acquired at an average cost of $19.46 per share, for a total transaction of $100,024.40. Following the purchase, the insider directly owned 61,238 shares in the company, valued at $1,191,691.48. This trade represents a 9.16% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Damien Mcdonald bought 13,035 shares of Enovis stock in a transaction on Friday, September 4th. The shares were acquired at an average cost of $19.15 per share, with a total value of $249,620.25. Following the completion of the acquisition, the chief executive officer owned 247,077 shares of the company’s stock, valued at $4,731,524.55. The trade was a 5.57% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired 23,293 shares of company stock worth $449,599 over the last three months. Insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

Several institutional investors have recently made changes to their positions in the business. Allworth Financial LP boosted its stake in shares of Enovis by 59.7% in the 2nd quarter. Allworth Financial LP now owns 1,744 shares of the company’s stock valued at $36,000 after purchasing an additional 652 shares in the last quarter. IFP Advisors Inc raised its position in Enovis by 5,590.5% in the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock valued at $25,000 after purchasing an additional 1,174 shares during the last quarter. Amundi boosted its position in Enovis by 2.3% during the 1st quarter. Amundi now owns 74,184 shares of the company’s stock worth $1,688,000 after buying an additional 1,677 shares during the period. Handelsbanken Fonder AB increased its position in Enovis by 9.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 21,117 shares of the company’s stock valued at $437,000 after acquiring an additional 1,800 shares during the period. Finally, Integrated Wealth Concepts LLC acquired a new position in Enovis in the 2nd quarter valued at approximately $39,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient outcomes and support the restoration of movement. Its portfolio serves orthopedic, rehabilitation and recovery markets, with products used by physicians, hospitals, physical therapists, athletic trainers and consumers.

The company’s offerings include orthopedic braces and supports, cold and compression therapy systems, rehabilitation equipment, electrical stimulation and ultrasound products, surgical implants and related technologies.